FDA PMA FDA Class 3 Approved 🇺🇸 United States

Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)

PMA: P010052 · Supplement: S004 · Decision Dec 16, 2009
Classifications
1
FEI Numbers
27
Registration Numbers
27

Basic Information

Device Name
Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
Trade Name
IMMULITE/IMMULITE 1000 AND IMMULITE 2000 ANTI-HBS ASSAYS
PMA Number
P010052
Supplement Number
S004
Device Class
FDA Class 3
Product Code
LOM
Generic Name
Test, hepatitis b (b core, be antigen, be antibody, b core igm)
Medical Specialty
Unknown
Advisory Committee
Microbiology
Decision
Approved
Decision Code
APPR
Decision Date
December 16, 2009
Date Received
February 25, 2008
Supplement Type
Normal 180 Day Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR IMMULITE/ IMMULITE 1000 ANDIMMULITE 2000 ANTI HBS ASSAY. THE DEVICE IS INDICATED FOR:IMMULITE/ IMMULITE 1000FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE OR IMMULITE 1000 ANALYZERS FOR THEQUALITATIVE AND QUANTITATIVE MEASUREMENT OF TOTAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN(ANTI-HBS) IN HUMAN SERUM AND PLASMA (HEPARINIZED). ASSAY RESULTS MAY BE USED AS AN AID IN THEDETERMINATION OF SUSCEPTIBILITY TO HEPATITIS B VIRUS (HBV) INFECTION FOR INDIVIDUALS PRIOR TO OR FOLLOWING HBV VACCINATION, OR WHERE VACCINATION STATUS IS UNKNOWN. ASSAY RESULTS MAY BE USED WITH OTHER HBV SEROLOGICAL MARKERS FOR THE LABORATORY DIAGNOSIS OF HBV DISEASE ASSOCIATED WITHHBV INFECTION. A REACTIVE ASSAY RESULT WILL ALLOW A DIFFERENTIAL DIAGNOSIS IN INDIVIDUALSDISPLAYING SIGNS AND SYMPTOMS OF HEPATITIS IN WHOM ETIOLOGY IS UNKNOWN.IMMULITE 2000FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE 2000 SYSTEMS AUTOMATED IMMUNOASSAYANALYZERS FOR THE QUALITATIVE AND QUANTITATIVE MEASUREMENT OF TOTAL ANTIBODIES TO THE HEPATITIS BSURFACE ANTIGEN (ANTI-HBS) IN HUMAN SERUM AND PLASMA (HEPARINIZED). ASSAY RESULTS MAY BE USEDAS AN AID IN THE DETERMINATION OF SUSCEPTIBILITY TO HEPATITIS B VIRUS (HBV) INFECTION FOR INDIVIDUALS PRIOR TO OR FOLLOWING I-IBV VACCINATION, OR WHERE VACCINATION STATUS IS UNKNOWN.ASSAY RESULTS MAY BE USED WITH OTHER HBV SEROLOGICAL MARKERS FOR THE LABORATORY DIAGNOSIS OF HBV DISEASE ASSOCIATED WITH HBV INFECTION. A REACTIVE ASSAY RESULT WILL ALLOW A DIFFERENTIALDIAGNOSIS IN INDIVIDUALS DISPLAYING SIGNS AND SYMPTOMS OF HEPATITIS IN WHOM ETIOLOGY ISUNKNOWN.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LOM Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)